Related by context. Frequent words. (Click for all words.) 72 CHEAP ONLINE PHARMACY LOW 69 PRICE GREAT DISCOUNT FREE 69 BEST ONLINE PHARMACY LOWEST 69 CHEAP ONLINE PHARMACY BEST 68 PRICES GREAT DISCOUNTS 67 RU EUROPE EEU EMRG 66 Inhibits 65 HCP #m #.# 65 Am J Clin 65 THE TREND CONTINUES LOWER 65 WEEK HIGH RECENTLY ECLIPSED 65 THE TREND CONTINUES DOWN 65 REACHES INITIAL SUPPORT LEVEL 64 WATCH FOR CONTINUED GAINS 64 Ascorbic Acid 64 THE TREND CONTINUES HIGHER 64 REACHES INITIAL RESISTANCE LEVEL 64 fumarate 64 PRICE FOR EXCELLENT 64 SET TO REBOUND AFTER 63 FDA Clears 63 PULLBACK IN SHARES OF 63 THE TREND CONTINUES UP 63 DING DONG THE 63 Drug Candidate 63 SET TO PULLBACK AFTER 62 TO REBOUND AFTER 62 SHARES UP 62 YESTERDAY 'S SELLOFF OF 62 REPORT ITS QUARTERLY 62 IS DOWN 62 Nephrol 62 BREAKS THROUGH RESISTANCE AT 62 RANGE OF 62 ABOVE AVERAGE VOLUME 61 Dexamethasone 61 Recombinant Human 61 BEARISH MOVING AVERAGE CROSSOVER 61 SET TO POSSIBLY PULLBACK 61 TO POTENTIALLY REBOUND AFTER 61 ISOCOUNTRY3 61 AT #/#/# 61 Receives FDA Clearance 61 % ADDITIONAL DOWNSIDE 61 HIGH SHARE PRICE TODAY 61 OUT IN SHARES 61 DOWNTREND SPOTTED IN SHARES 61 % POTENTIAL UPSIDE 61 VOLUME WATCH FOR PULLBACK 61 THE WINNING STREAK 61 YESTERDAY 'S RALLY OF 61 Guides FY# Quick Facts 61 induced apoptosis 61 STOCK ON 61 SMARTREND RESEARCH REPORT AVAILABLE 61 SEE CONTINUED UPWARD MOMENTUM 60 TO PULLBACK AFTER GAINING 60 TRADING RANGE ABOVE 60 #.#X ABOVE AVERAGE VOLUME 60 OFFERS INVESTORS BETTER VALUE 60 CHANCE OF 60 SHARES COULD POTENTIALLY PULLBACK 60 BLN COUPON 60 CONTINUATION 60 injection USP 60 ARE MOVING HIGHER ON 60 REBOUND IN SHARES 59 Overexpression 59 CROSSES PIVOT POINT RESISTANCE 59 lispro 59 SLAY 59 Test Strips 59 PHARM 59 ASST 59 NEXT SUPPORT LEVEL FOR 59 voriconazole 59 BREAKS THROUGH SUPPORT 59 EARNINGS LOOK AHEAD 59 NEXT RESISTANCE LEVEL FOR 59 VOLUME WATCH FOR POTENTIAL 59 % ABOVE ITS 59 SHARES COULD PULLBACK 58 CROSSES PIVOT POINT SUPPORT 58 % SELL OFF 58 ASSOC 58 Phosphorylation 58 Enzymatic 58 TO APPROACH RESISTANCE AT 58 MOVE UP 58 Preclinical Data 58 Intranasal 58 % BELOW ITS 58 DAY TRADING RANGE 58 TO POTENTIALLY PULLBACK AFTER 58 TO DATE ON 58 Epithelial 58 GROUP LTD 58 Sertraline 58 FDA Accepts 57 TO APPROACH SUPPORT 57 APPROACHES NEW UPSIDE TARGET